Imprecision in tuberculosis infection outcomes: implications for non-inferiority vaccine trials
Tuberculosis vaccine non-inferiority trials using an infection primary outcome must be designed and interpreted accounting for the specificity of the tools used to measure infection, otherwise they risk declaring non-inferiority by default.
Authors
- Daniel J. Grint (ORCID: https://orcid.org/0000-0001-8001-6544)
- Gavin Churchyard (ORCID: https://orcid.org/0000-0002-4269-3699)
- Richard G White
- Molebogeng Rangaka
- Andrew Fiore-Gartland
- Frank Cobelens
- Alberto L Garcia-Basteiro
Institutions
- University of the Witwatersrand (ZA)
- Fred Hutch Cancer Center (US)
- London School of Hygiene & Tropical Medicine (GB)
- Centro de Investigación Biomédica en Red (ES)
- Manhiça Health Research Centre (MZ)
- Aurum Institute (ZA)
- Amsterdam Institute for Global Health and Development (NL)
- Centre for Global Health Research (CA)
- Barcelona Institute for Global Health (ES)
- Public Health Service of Amsterdam (NL)
- University College London (GB)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- International Journal of Epidemiology
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1093/ije/dyag034
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00